High expression of fibronectin is associated with poor prognosis, cell proliferation and malignancy via the NF-κB/p53-apoptosis signaling pathway in colorectal cancer

Yi,Wenzhong; Xiao,Enhua; Ding,Ru; Luo,Ping; Yang,Yi

doi:10.3892/or.2016.5177

High expression of fibronectin is associated with poor prognosis, cell proliferation and malignancy via the NF-κB/p53-apoptosis signaling pathway in colorectal cancer

Authors:
- Wenzhong Yi
- Enhua Xiao
- Ru Ding
- Ping Luo
- Yi Yang
View Affiliations

Affiliations: Medical Imaging Center, First People's Hospital of Huaihua City, Huaihua, Hunan 418000, P.R. China, Department of Radiology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P.R. China, Department of Gastroenterology, First People's Hospital of Huaihua City, Huaihua, Hunan 418000, P.R. China
Published online on: October 17, 2016 https://doi.org/10.3892/or.2016.5177
Pages: 3145-3153
Copyright: © Yi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fibronectin is a glycoprotein of the extracellular matrix, and regulates the processes of self-renewal and cell cycle progression. This study aimed to investigate fibronectin expression in colorectal cancer (CRC) and elucidate the effects of fibronectin on CRC by using a knockdown approach. Immunohistochemistry was used to evaluate the expression of fibronectin in 107 CRC patient tissues and gene expression was detected by real-time quantitative PCR (qPCR) and western blot analysis. Based on the above findings, the association among fibronectin expression, clinicopathological features and prognosis was analyzed. Next, fibronectin expression was silenced by small-interfering RNAs (siRNAs) and the effects of fibronectin siRNA transfection on CRC cells and tumor growth in nude mice were assessed. Expression of genes in the NF-κB/p53-apoptosis signaling pathway were analyzed after fibronectin siRNA transfection both in vitro and in vivo. Based on the results, high expression of fibronectin was observed both in the CRC tissues and CRC cell lines. The expression level was positively correlated with TNM stage (P=0.0025) and distant metastasis (P=0.0013). By Kaplan-Meier analysis, the patients with low fibronectin expression had a longer survival time comparing to those with relatively high expression. Knockdown of fibronectin suppressed SW480 cell proliferation, migration and invasion. In addition, knockdown of fibronectin led to S phase cell cycle arrest. The following study showed that the NF-κB/p53-apoptosis signaling pathway in CRC was affected by fibronectin knockdown. Tumor formation was also depressed by fibronectin siRNA transfection of CRC cells. These results showed the significant role of fibronectin in CRC tissues and cell lines. Therefore, fibronectin may be regarded as a potential target for CRC treatment.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Wang S, Xiang J, Li Z, Lu S, Hu J, Gao X, Yu L, Wang L, Wang J, Wu Y, et al: A plasma microRNA panel for early detection of colorectal cancer. Int J Cancer. 136:152–161. 2015. View Article : Google Scholar : PubMed/NCBI
3	Nishihara R, Morikawa T, Kuchiba A, Lochhead P, Yamauchi M, Liao X, Imamura Y, Nosho K, Shima K, Kawachi I, et al: A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification. Am J Epidemiol. 178:84–100. 2013. View Article : Google Scholar : PubMed/NCBI
4	Pierschbacher MD and Ruoslahti E: Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature. 309:30–33. 1984. View Article : Google Scholar : PubMed/NCBI
5	Pankov R and Yamada KM: Fibronectin at a glance. J Cell Sci. 115:3861–3863. 2002. View Article : Google Scholar : PubMed/NCBI
6	Francis SE, Goh KL, Hodivala-Dilke K, Bader BL, Stark M, Davidson D and Hynes RO: Central roles of α5β1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arterioscler Thromb Vasc Biol. 22:927–933. 2002. View Article : Google Scholar : PubMed/NCBI
7	Rybak J-N, Roesli C, Kaspar M, Villa A and Neri D: The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res. 67:10948–10957. 2007. View Article : Google Scholar : PubMed/NCBI
8	Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, Leprini A, Borsi L, Castellani P, Zardi L, et al: Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res. 9:571–579. 2003.PubMed/NCBI
9	Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, Arvanitis DL, Agnantis NJ and Pavlidis N: Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: Their prognostic value and role in tumour invasion and progression. Eur J Cancer. 38:2362–2370. 2002. View Article : Google Scholar : PubMed/NCBI
10	Saad S, Gottlieb DJ, Bradstock KF, Overall CM and Bendall LJ: Cancer cell-associated fibronectin induces release of matrix metalloproteinase-2 from normal fibroblasts. Cancer Res. 62:283–289. 2002.PubMed/NCBI
11	Meng XN, Jin Y, Yu Y, Bai J, Liu GY, Zhu J, Zhao YZ, Wang Z, Chen F, Lee KY, et al: Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Br J Cancer. 101:327–334. 2009. View Article : Google Scholar : PubMed/NCBI
12	Xing H, Weng D, Chen G, Tao W, Zhu T, Yang X, Meng L, Wang S, Lu Y and Ma D: Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett. 261:108–119. 2008. View Article : Google Scholar : PubMed/NCBI
13	Stanton H, Gavrilovic J, Atkinson SJ, d'Ortho MP, Yamada KM, Zardi L and Murphy G: The activation of ProMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form. J Cell Sci. 111:2789–2798. 1998.PubMed/NCBI
14	Esparza J, Vilardell C, Calvo J, Juan M, Vives J, Urbano-Márquez A, Yagüe J and Cid MC: Fibronectin upregulates gelatinase B (MMP-9) and induces coordinated expression of gelatinase A (MMP-2) and its activator MT1-MMP (MMP-14) by human T lymphocyte cell lines. A process repressed through RAS/MAP kinase signaling pathways. Blood. 94:2754–2766. 1999.PubMed/NCBI
15	La Fleur M, Beaulieu AD, Kreis C and Poubelle P: Fibronectin gene expression in polymorphonuclear leukocytes. Accumulation of mRNA in inflammatory cells. J Biol Chem. 262:2111–2115. 1987.PubMed/NCBI
16	Hines KL, Kulkarni AB, McCarthy JB, Tian H, Ward JM, Christ M, McCartney-Francis NL, Furcht LT, Karlsson S and Wahl SM: Synthetic fibronectin peptides interrupt inflammatory cell infiltration in transforming growth factor beta 1 knockout mice. Proc Natl Acad Sci USA. 91:5187–5191. 1994. View Article : Google Scholar : PubMed/NCBI
17	Center MM, Jemal A and Ward E: International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 18:1688–1694. 2009. View Article : Google Scholar : PubMed/NCBI
18	Huang Z, Huang D, Ni S, Peng Z, Sheng W and Du X: Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 127:118–126. 2010. View Article : Google Scholar : PubMed/NCBI
19	Srivastava S, Verma M and Henson DE: Biomarkers for early detection of colon cancer. Clin Cancer Res. 7:1118–1126. 2001.PubMed/NCBI
20	Fornaro M, Plescia J, Chheang S, Tallini G, Zhu YM, King M, Altieri DC and Languino LR: Fibronectin protects prostate cancer cells from tumor necrosis factor-α-induced apoptosis via the AKT/survivin pathway. J Biol Chem. 278:50402–50411. 2003. View Article : Google Scholar : PubMed/NCBI
21	Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, Chilvers ER, Dransfield I, Donnelly SC, Strieter R, et al: Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med. 5:662–668. 1999. View Article : Google Scholar : PubMed/NCBI
22	Shibata K, Kikkawa F, Nawa A, Thant AA, Naruse K, Mizutani S and Hamaguchi M: Both focal adhesion kinase and c-Ras are required for the enhanced matrix metalloproteinase 9 secretion by fibronectin in ovarian cancer cells. Cancer Res. 58:900–903. 1998.PubMed/NCBI
23	Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O and Khalifa A: Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. J Urol. 168:465–469. 2002. View Article : Google Scholar : PubMed/NCBI
24	Shibayama H, Tagawa S, Hattori H, Inoue R, Katagiri S and Kitani T: Laminin and fibronectin promote the chemotaxis of human malignant plasma cell lines. Blood. 86:719–725. 1995.PubMed/NCBI
25	Baldwin AS Jr: The NF-κB and IκB proteins: New discoveries and insights. Annu Rev Immunol. 14:649–683. 1996. View Article : Google Scholar : PubMed/NCBI
26	Beg AA and Baltimore D: An essential role for NF-kappaB in preventing TNF-α-induced cell death. Science. 274:782–784. 1996. View Article : Google Scholar : PubMed/NCBI
27	Chariot A: The NF-kappaB-independent functions of IKK subunits in immunity and cancer. Trends Cell Biol. 19:404–413. 2009. View Article : Google Scholar : PubMed/NCBI
28	Porter AG and Jänicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999. View Article : Google Scholar : PubMed/NCBI
29	Feng Z, Hu W, Rajagopal G and Levine AJ: The tumor suppressor p53: Cancer and aging. Cell Cycle. 7:842–847. 2008. View Article : Google Scholar : PubMed/NCBI
30	Curtin NJ: PARP inhibitors for cancer therapy. Expert Rev Mol Med. 7:1–20. 2005. View Article : Google Scholar : PubMed/NCBI
31	Mackey TJ, Borkowski A, Amin P, Jacobs SC and Kyprianou N: bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology. 52:1085–1090. 1998. View Article : Google Scholar : PubMed/NCBI
32	Kaufmann SH and Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 256:42–49. 2000. View Article : Google Scholar : PubMed/NCBI